SECURITIES AND EXCHANGE COMMISSION
WASHINGTON, D. C. 20549
FORM 8-K
CURRENT REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE
SECURITIES EXCHANGE ACT OF 1934
Date of Report (Date of earliest event reported): May 29, 2001
INTRABIOTICS PHARMACEUTICALS, INC.
(Exact name of registrant as specified in its charter)
DELAWARE
(State or other jurisdiction of incorporation)
0-29993 94-3200380
(Commission File No.) (IRS Employer Identification No.)
2021 STIERLIN COURT
MOUNTAIN VIEW, CALIFORNIA 94043
(Address of principal executive offices and zip code)
Registrant's telephone number, including area code: (650) 526-6800
------------------------------
ITEM 5. OTHER EVENTS
On May 29, 2001, IntraBiotics Pharmaceuticals, Inc. and Biosearch Italia S.p.A.
announced an amendment to the License and Supply Agreement, dated May 8, 1998,
for the development and commercialization of certain formulations of ramoplanin
in North America for the treatment or prevention of human disease. The press
release announcing the amendment is filed as Exhibit 99.1 hereto.
ITEM 7. FINANCIAL STATEMENTS AND EXHIBITS
(c) EXHIBITS.
99.1 Press Release, dated May 29, 2001, entitled "IntraBiotics
and Biosearch Italia S.p.A. Amend Collaboration on Ramoplanin."
1
SIGNATURE
Pursuant to the requirements of the Securities Exchange Act of 1934, the
registrant has duly caused this report to be signed on its behalf by the
undersigned, thereunto duly authorized.
INTRABIOTICS PHARMACEUTICALS, INC.
Dated: May 29, 2001 By: /s/ SANDRA WROBEL
-------------------------------------
Sandra Wrobel
Chief Financial Officer and Vice
President, Business Operations
2
INDEX TO EXHIBITS
99.1 Press Release, dated May 29, 2001, entitled "IntraBiotics and
Biosearch Italia S.p.A. Amend Collaboration on Ramoplanin."